Pharmaceuticals, Biotechnology and Life Sciences
Leigh Ann Pusey will join Eli Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, todayhas reported financial results for the fiscal quarter ended March 31, 2017.
Bristol-Myers Squibb (BMS) and Calithera Biosciences have expanded their existing collaboration to evaluate BMS’s Opdivo in combination with Calithera’s CB-839 in patients with non-small cell lung cancer (NSCLC) and melanoma.
Allergan announced that it expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in the coming weeks.
AstraZeneca and its subsidiary MedImmune have reported that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.
Navamedic, a Norwegian medtech and pharmaceutical products company, has reported loss before tax of €0.3 million for the first quarter of 2017, which is increase compared to €0.7 million for the same period last year.
Biocartis Group has appointed Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017.
Healthcare conglomerate Johnson & Johnson <JNJ.N> said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.
Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.